Skip to main content

MDL Panel Rejects To Consolidate Belviq Lawsuits

MDL Panel Rejects To Consolidate Belviq Lawsuits

MDL Panel Rejects To Consolidate Belviq Lawsuits

Introduction

A Judicial Panel has refused to centralize Belviq lawsuits against Eisai Inc. and Arena Pharmaceuticals Inc. in an MDL stating there are too few lawsuits filed against the manufacturers post the recall of the drug. 

The attorneys who are asking for consolidating the Belviq litigation claim that the lawsuits will grow into thousands in the coming days, but the fact is that only a small number of Belviq lawsuits have been filed since last 18 months when the U.S. Food and Drug Administration (FDA) ordered to recall the drug from the U.S. market.

As per the court documents, the Belviq manufacturers face 12 personal injury suits and a proposed class action with similar allegations that Belviq causes cancer. The panel informed that the plaintiffs claimed the drug resulted in a variety of cancers like breast cancer, thyroid cancer, colorectal cancer, and cancer of the parotid gland.

In February 2020, the FDA ordered the removal of the drug from the market, considering clinical studies that highlighted the growing number of cancer patients.

Belviq is a weight loss drug used to treat obesity. The manufacturers conducted various studies on the animals before introducing the drug in the drug market. The studies concluded that Belviq could cause cancer and need additional testing. However, the manufacturers ignored the studies and manipulated the results of the animal studies to trick the FDA to approve the drug.

Earlier, manufacturers of Belviq, Eisai Inc., and Arena Pharmaceuticals also opposed the consolidation of the cases.

Comments

Restricted HTML

  • Allowed HTML tags: <a href hreflang> <em> <strong> <cite> <blockquote cite> <code> <ul type> <ol start type> <li> <dl> <dt> <dd> <h2 id> <h3 id> <h4 id> <h5 id> <h6 id>
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.

Latest News

Purdue, Sacklers Agree to $7.4B Opioid Settlement

Categories: Opioids

Purdue Pharma and its owners, the Sackler family, have agreed to a $7.4 billion settlement to resolve thousands of lawsuits accusing the…

Paraquat Trials Scheduled for October 2025 & April 2026

Categories: Paraquat

A U.S. District Judge overseeing thousands of federal

UGA College of Pharmacy Gets $1M+ to Fight Opioid Crisis

Categories: Opioids

Faculty from the University of Georgia’s College of Pharmacy have been awarded a nearly $1.2 million grant from the Georgia Opioid Crisis…

Get 5 Free Medical Record Reviews – No Risk, No Contracts!      
Only 10 firms will be accepted!

Valid until February 28, 2025.